GSK plc reported Q3 2024 sales of £8.0 billion, declining 2% year-over-year, primarily due to a 15% drop in vaccine sales. Specialty Medicines grew 19%, driven by strong HIV (up 12%) and oncology (up 94%) performances, while overall core EPS increased 5%, and a dividend of 15p was declared for Q3 2024.